150 related articles for article (PubMed ID: 32623363)
1. Neurological manifestation of immune system dysregulation resulting from CTLA-4 receptor mutation: a case report.
Kolcava J; Litzman J; Bednarik J; Stulik J; Stourac P
Mult Scler Relat Disord; 2020 Oct; 45():102313. PubMed ID: 32623363
[TBL] [Abstract][Full Text] [Related]
2. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
3. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
[TBL] [Abstract][Full Text] [Related]
4. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
5. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
Schwab C; Gabrysch A; Olbrich P; Patiño V; Warnatz K; Wolff D; Hoshino A; Kobayashi M; Imai K; Takagi M; Dybedal I; Haddock JA; Sansom DM; Lucena JM; Seidl M; Schmitt-Graeff A; Reiser V; Emmerich F; Frede N; Bulashevska A; Salzer U; Schubert D; Hayakawa S; Okada S; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Sumnik Z; Sediva A; Slatter M; Arkwright PD; Cant A; Lorenz HM; Giese T; Lougaris V; Plebani A; Price C; Sullivan KE; Moutschen M; Litzman J; Freiberger T; van de Veerdonk FL; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Speckmann C; Ehl S; Leichtner A; Blumberg R; Franke A; Snapper S; Zeissig S; Cunningham-Rundles C; Giulino-Roth L; Elemento O; Dückers G; Niehues T; Fronkova E; Kanderová V; Platt CD; Chou J; Chatila TA; Geha R; McDermott E; Bunn S; Kurzai M; Schulz A; Alsina L; Casals F; Deyà-Martinez A; Hambleton S; Kanegane H; Taskén K; Neth O; Grimbacher B
J Allergy Clin Immunol; 2018 Dec; 142(6):1932-1946. PubMed ID: 29729943
[TBL] [Abstract][Full Text] [Related]
6. CNS demyelination associated with immune dysregulation and a novel
Kaninia S; Grammatikos A; Urankar K; Renowden SA; Patel NK; Gompels MM; Rice CM
Mult Scler; 2021 Aug; 27(9):1464-1467. PubMed ID: 34097529
[TBL] [Abstract][Full Text] [Related]
7. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.
Zeissig S; Petersen BS; Tomczak M; Melum E; Huc-Claustre E; Dougan SK; Laerdahl JK; Stade B; Forster M; Schreiber S; Weir D; Leichtner AM; Franke A; Blumberg RS
Gut; 2015 Dec; 64(12):1889-97. PubMed ID: 25367873
[TBL] [Abstract][Full Text] [Related]
8. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.
Jain N; Nguyen H; Chambers C; Kang J
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1524-8. PubMed ID: 20080649
[TBL] [Abstract][Full Text] [Related]
9. Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.
Verma N; Burns SO; Walker LSK; Sansom DM
Clin Exp Immunol; 2017 Oct; 190(1):1-7. PubMed ID: 28600865
[TBL] [Abstract][Full Text] [Related]
10. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.
Hayakawa S; Okada S; Tsumura M; Sakata S; Ueno Y; Imai K; Morio T; Ohara O; Chayama K; Kobayashi M
J Clin Immunol; 2016 Jan; 36(1):28-32. PubMed ID: 26644313
[TBL] [Abstract][Full Text] [Related]
11. Current understanding of CTLA-4: from mechanism to autoimmune diseases.
Hossen MM; Ma Y; Yin Z; Xia Y; Du J; Huang JY; Huang JJ; Zou L; Ye Z; Huang Z
Front Immunol; 2023; 14():1198365. PubMed ID: 37497212
[TBL] [Abstract][Full Text] [Related]
12. A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
Zaremehrjardi F; Baniadam L; Seif F; Arshi S; Bemanian MH; Shokri S; Rezaeifar A; Fallahpour M; Nabavi M
Iran J Immunol; 2020 Sep; 17(3):244-249. PubMed ID: 32996901
[TBL] [Abstract][Full Text] [Related]
13. Heterozygous
Mahat U; Ambani NM; Rotz SJ; Radhakrishnan K
Pediatr Hematol Oncol; 2021 Oct; 38(7):658-662. PubMed ID: 33900894
[TBL] [Abstract][Full Text] [Related]
14. The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis.
Basile MS; Bramanti P; Mazzon E
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893056
[TBL] [Abstract][Full Text] [Related]
15. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Kuehn HS; Ouyang W; Lo B; Deenick EK; Niemela JE; Avery DT; Schickel JN; Tran DQ; Stoddard J; Zhang Y; Frucht DM; Dumitriu B; Scheinberg P; Folio LR; Frein CA; Price S; Koh C; Heller T; Seroogy CM; Huttenlocher A; Rao VK; Su HC; Kleiner D; Notarangelo LD; Rampertaap Y; Olivier KN; McElwee J; Hughes J; Pittaluga S; Oliveira JB; Meffre E; Fleisher TA; Holland SM; Lenardo MJ; Tangye SG; Uzel G
Science; 2014 Sep; 345(6204):1623-1627. PubMed ID: 25213377
[TBL] [Abstract][Full Text] [Related]
16. An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome.
Sic H; Speletas M; Cornacchione V; Seidl M; Beibel M; Linghu B; Yang F; Sevdali E; Germenis AE; Oakeley EJ; Vangrevelinghe E; Sailer AW; Traggiai E; Gram H; Eibel H
Front Immunol; 2017; 8():1824. PubMed ID: 29375547
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 expressed by FOXP3
Klocke K; Holmdahl R; Wing K
Immunology; 2017 Sep; 152(1):125-137. PubMed ID: 28497863
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.
Stumpf M; Zhou X; Chikuma S; Bluestone JA
Eur J Immunol; 2014 Jun; 44(6):1737-46. PubMed ID: 24648182
[TBL] [Abstract][Full Text] [Related]
19. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
Wing K; Yamaguchi T; Sakaguchi S
Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
[TBL] [Abstract][Full Text] [Related]
20. Lessons from CTLA-4 deficiency and checkpoint inhibition.
Lo B; Abdel-Motal UM
Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
